Plus Therapeutics Inc PSTV

Healthcare Biotechnology

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

NDAQ:PSTV - Post by User

Plus Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson May 06, 2024 3:30pm

43 Views

Post# 36025587

Plus Therapeutics Announces Private Placement Financing of u

JUST IN: $PSTV Plus Therapeutics Announces Private Placement Financing of up to $18 MillionAUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today ...PSTV - Plus Therapeutics Announces Private Placement Financing of up to $18 Million

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China